- Home
- STAI vs CLGN Comparison
STAI vs CLGN Comparison
Compare STAI & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- CLGN
- Stock Information
- Founded
- STAI 2011
- CLGN 2004
- Country
- STAI United States
- CLGN Israel
- Employees
- STAI N/A
- CLGN N/A
- Industry
- STAI
- CLGN Industrial Specialties
- Sector
- STAI
- CLGN Health Care
- Exchange
- STAI Nasdaq
- CLGN Nasdaq
- Market Cap
- STAI 16.6M
- CLGN 19.1M
- IPO Year
- STAI N/A
- CLGN N/A
- Fundamental
- Price
- STAI $0.68
- CLGN $1.44
- Analyst Decision
- STAI
- CLGN Strong Buy
- Analyst Count
- STAI 0
- CLGN 2
- Target Price
- STAI N/A
- CLGN $11.50
- AVG Volume (30 Days)
- STAI 485.0K
- CLGN 90.0K
- Earning Date
- STAI 01-01-0001
- CLGN 08-19-2025
- Dividend Yield
- STAI N/A
- CLGN N/A
- EPS Growth
- STAI N/A
- CLGN N/A
- EPS
- STAI N/A
- CLGN N/A
- Revenue
- STAI $542,166.00
- CLGN $2,472,000.00
- Revenue This Year
- STAI N/A
- CLGN $1,999.42
- Revenue Next Year
- STAI N/A
- CLGN $69.81
- P/E Ratio
- STAI N/A
- CLGN N/A
- Revenue Growth
- STAI N/A
- CLGN N/A
- 52 Week Low
- STAI $0.62
- CLGN $1.31
- 52 Week High
- STAI $9.07
- CLGN $5.45
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- CLGN 43.95
- Support Level
- STAI N/A
- CLGN $1.33
- Resistance Level
- STAI N/A
- CLGN $1.48
- Average True Range (ATR)
- STAI 0.00
- CLGN 0.10
- MACD
- STAI 0.00
- CLGN 0.03
- Stochastic Oscillator
- STAI 0.00
- CLGN 56.52
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.